Ferrocene and TLR7 / 8 agonist co-linked nanoparticles and preparation method and application thereof

Nanoparticles formed by self-assembly of amphiphilic block copolymer synthesized by RAFT polymerization solve the problems of instability in divalent iron ion delivery and poor solvent properties of TLR7/8 agonist, and achieve targeted aggregation of drugs in tumor sites and immune system activation enhances the anti-tumor treatment effect and reduces toxic side effects.

CN115400223BActive Publication Date: 2024-11-22SHANDONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211199536.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-29
Publication Date
2024-11-22
Estimated Expiration
2042-09-29

AI Technical Summary

Technical Problem

The delivery of divalent iron ions in the prior art limits the application of chemokinetic therapy (CDT) in tumor therapy, and the poor solvent properties of TLR7/8 agonists such as imiquimod limit their in other types. Application on tumor cells leads to systemic distribution of drugs and toxic side effects.

Method used

The amphiphilic block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ were synthesized by RAFT polymerization to form a nano-level drug delivery platform N@Fc/IM through self-assembly, using ferrocene and TLR7/8 agonists Co-connection ensures the hydrophilicity and stability of nanoparticles, avoids drug leakage and systemic distribution, and promotes targeted aggregation of tumor sites.

Benefits of technology

The targeted aggregation of drugs in the tumor site is achieved, induced oxidative death of cells through the Fenton reaction, activated the immune system, enhanced the ability to attack the tumor, reduced toxic side effects, and had good anti-tumor treatment effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115400223B_ABST
    Figure CN115400223B_ABST
Patent Text Reader

Abstract

The present invention provides a ferrocene and TLR7 / 8 agonist co-linked nanoparticle and a preparation method and application thereof, belonging to the technical field of biomedicine and molecular biology. The present invention adopts RAFT polymerization to synthesize amphiphilic block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ, which can spontaneously assemble into a nanoscale drug delivery platform N@Fc / IM in a PBS system, which can induce cell oxidative death through Fenton reaction while fully mobilizing the immune system, so that it can be used for anti-tumor treatment, while avoiding the greater toxic side effects caused by direct delivery, and therefore has good practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine and molecular biology, and specifically relates to a ferrocene and TLR7 / 8 agonist co-linked nanoparticle and a preparation method and application thereof. Background Art

[0002] The information disclosed in the background of the invention is only intended to enhance the understanding of the overall background of the invention and should not be necessarily regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Chemodynamic therapy (CDT) is defined as an in situ treatment mode that utilizes the conditions of slight acidity and excess hydrogen peroxide (H2O2) in the tumor microenvironment, uses transition metal nanomaterials as catalysts, and catalyzes H2O2 to produce highly toxic reactive oxygen species such as hydroxyl radicals (·OH) through Fenton reactions or Fenton-like reactions, thereby inducing tumor cell apoptosis. Iron-based CDT has been widely studied and reported in recent years, and the realization of CDT effects also depends on the delivery efficiency of divalent iron ions. Since divalent iron is in an unstable state and is easily oxidized to a trivalent state, there are huge challenges in the delivery of divalent iron ions. In recent years, studies have shown that the iron in ferrocene (FcA) is in a divalent state, and the large dissociation energy of the iron cyclopentadienyl (Fe-Cp) bond (≈90 kcalmol-1) is relatively stable. Its discovery has brought hope for the construction of a new Fenton reaction reagent.

[0004] In addition to cell death directly induced by Fenton reaction, reactive oxygen species produced during CDT can also promote immunogenic cell death in tumors. This process is accompanied by the production of calreticulin (CRT), which in turn activates professional antigen-presenting dendritic cells (DCs). Mature DC cells recruit T lymphocytes to the tumor site through the binding between CD40-CD40L, CD86-CD28, and MHC-TCR. A large number of aggregated T lymphocytes will jointly eliminate tumor cells.

[0005] In order to further stimulate and mobilize immune cells and promote the maximization of T lymphocyte recruitment, studies have shown that imidazoquinoline TLR7 / 8 agonists, as an immune adjuvant, have very strong DC activation ability. Among them, imiquimod has been approved for the treatment of skin cancer. However, the extremely poor solubility of imiquimod limits its application in other types of tumor cells. Many researchers have made different modifications and transformations to this small molecule in order to obtain better compounds. Among them, IMDQ is a more successful imidazoquinoline analogue with stronger activity and better solubility. It is worth mentioning that the fatty amino group on IMDQ can be chemically bonded to other carriers to facilitate drug delivery. Summary of the invention

[0006] In view of the deficiencies in the prior art, the purpose of the present invention is to provide a ferrocene and TLR7 / 8 agonist co-linked nanoparticles and their preparation method and application. The present invention uses RAFT polymerization to synthesize amphiphilic block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ, both of which can spontaneously assemble into a nanoscale drug delivery platform N@Fc / IM in a PBS system, which can induce cell oxidative death through the Fenton reaction while fully mobilizing the immune system, thereby being used for anti-tumor treatment, while avoiding the greater toxic side effects caused by direct delivery. Based on the above research results, the present invention is completed.

[0007] In order to achieve the above technical objectives, the technical solution adopted by the present invention is as follows:

[0008] In a first aspect of the present invention, a ferrocene and TLR7 / 8 agonist co-linked nanoparticle is provided, wherein the ferrocene and TLR7 / 8 agonist co-linked nanoparticle (N@Fc / IM) is obtained by self-assembly of block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ;

[0009] The structural formulas of the block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ are shown in Formula I and Formula II below:

[0010]

[0011] The nanoparticle shell is a pHEA end, which provides a hydrophilic part for the nanoparticle, ensuring the overall stability and hydrophilicity of the nanoparticle; the drug in the inner core is connected to the polymer through chemical action to prevent leakage of the drug in the systemic circulation and avoid toxicity caused by systemic distribution.

[0012] The second aspect of the present invention provides a method for preparing the above-mentioned nanoparticles, the preparation method comprising:

[0013] S1. Synthesis of pHEA-b-pFcA;

[0014] S2, synthesis of pHEA-b-pIMDQ;

[0015] S3. Adding the pHEA-b-pFcA and pHEA-b-pIMDQ into a buffer solution to obtain the pHEA-b-pFcA and pHEA-b-pIMDQ by self-assembly.

[0016] The third aspect of the present invention provides the use of the above-mentioned nanoparticles in the preparation of anti-tumor drugs.

[0017] A fourth aspect of the present invention provides an anti-tumor drug, wherein the active ingredient of the anti-tumor drug comprises the above-mentioned nanoparticles.

[0018] According to the present invention, the medicament further comprises at least one pharmaceutically inactive ingredient.

[0019] A fifth aspect of the present invention provides a method for treating tumors, comprising administering a therapeutically effective dose of the above-mentioned nanoparticles or drugs to a subject.

[0020] Beneficial technical effects of one or more of the above technical solutions:

[0021] The above technical solution provides a ferrocene and TLR7 / 8 agonist co-linked nanoparticles, and the above technical solution selects ferrocene molecules stabilized by divalent iron and IMDQ, which is more active and easy to modify, to combine, and fully mobilize the immune system while inducing cell oxidative death through the Fenton reaction. There are large differences in the physicochemical properties of the two small molecule drugs, and direct delivery will lead to systemic distribution of the drug, thereby causing greater toxic side effects. For this reason, the nano-delivery strategy came into being, which provides convenience for achieving targeted aggregation of drugs at the tumor site. The present invention synthesizes amphiphilic block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ by RAFT polymerization. Both can spontaneously assemble into a nanoscale drug delivery platform N@Fc / IM in a PBS system. The pHEA end provides a hydrophilic part for N@Fc / IM, ensuring the overall stability and hydrophilicity of the nanoparticles. The drug in the core is chemically connected to the polymer to prevent the drug from leaking in the systemic circulation and avoid toxicity caused by systemic distribution. After intravenous injection, N@Fc / IM can mainly rely on passive targeting to accumulate in tumor tissues. After being engulfed by cells, the ferrocene in the nanoparticles will undergo a Fenton reaction when it meets excess hydrogen peroxide to produce a large number of hydroxyl free radicals. This process is accompanied by the occurrence of immunogenic cell death of tumor cells. The calreticulin gradually exposed by tumor cells and the immune adjuvant IMDQ together activate the maturation of DC cells and widely mobilize the recruitment of T lymphocytes, providing a powerful weapon for the removal and attack of tumors. Therefore, the present invention has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0023] Figure 1 The figures are the synthesis diagrams of monomer APMA-FcA and monomer PFPA in the embodiments of the present invention; a is the synthesis of APMA-FcA; b is the synthesis of PFPA;

[0024] Figure 2 is the APMA-FcA in the embodiment of the present invention 1 H-NMR results;

[0025] Figure 3 is the PFPA in the embodiment of the present invention. 1 H-NMR results;

[0026] Figure 4 This is the RAFT polymerization route of the block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ in the embodiments of the present invention;

[0027] Figure 5 is pHEA in the embodiment of the present invention 1 H-NMR results;

[0028] Figure 6 is pHEA-b-pFcA in the embodiment of the present invention 1 H-NMR results;

[0029] Figure 7 is pHEA-b-pPFP in the embodiment of the present invention 1 H-NMR results;

[0030] Figure 8 is the molecular weight result of the polymer in the embodiment of the present invention;

[0031] Fig. 9 A successful connection diagram of IMDQ in an embodiment of the present invention;

[0032] Fig.10 Schematic diagram of the construction of nanoparticles;

[0033] Fig.11 Characterization of nanoparticles in the embodiment of the present invention; a is the particle size distribution diagram of N@FcA; b is the particle size distribution diagram of N@IMDQ; c is the particle size distribution diagram of N@Fc / IM; d is the zeta potential and representative transmission electron microscopy image of N@FcA; e is the zeta potential and representative transmission electron microscopy image of N@IMDQ; f is the zeta potential and representative transmission electron microscopy image of N@Fc / IM;

[0034] Fig.12 The hydroxyl radical detection in the embodiment of the present invention; wherein a is methylene blue for detecting hydroxyl radicals; b is terephthalic acid as a probe for detecting hydroxyl radicals;

[0035] Fig.13 The cellular uptake of nanoparticles in the embodiments of the present invention;

[0036] Fig.14 is the cytotoxicity of the nanoparticles in the embodiments of the present invention;

[0037] Fig.15 Schematic diagram of nanoparticles activating DC cells in an embodiment of the present invention;

[0038] Fig.16 The nanoparticles in the embodiments of the present invention promote the maturation of DC cells; wherein, a means that the nanoparticles promote the expression of CD86 on the surface of DC cells; b means that the nanoparticles promote the expression of CD40 on the surface of DC cells; c means that the nanoparticles promote the expression of MHC-II on the surface of DC cells;

[0039] Fig.17 It is a graph showing the tumor growth curves of different groups of mice in the examples of the present invention. DETAILED DESCRIPTION

[0040] It should be noted that the following detailed descriptions are all illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0041] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0042] The present invention is further described in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out according to conventional conditions or the conditions recommended by the reagent company; the reagents and consumables used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0043] In a typical embodiment of the present invention, a ferrocene and TLR7 / 8 agonist co-linked nanoparticle is provided, wherein the ferrocene and TLR7 / 8 agonist co-linked nanoparticle (N@Fc / IM) is obtained by self-assembly of block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ;

[0044] The structural formulas of the block copolymers pHEA-b-pFcA and pHEA-b-pIMDQ are shown in Formula I and Formula II below:

[0045]

[0046] The nanoparticle shell is a pHEA end, which provides a hydrophilic part for the nanoparticle, ensuring the overall stability and hydrophilicity of the nanoparticle; the drug in the inner core is connected to the polymer through chemical action to prevent leakage of the drug in the systemic circulation and avoid toxicity caused by systemic distribution.

[0047] The nanoparticles have uniform particle sizes, with an average particle size of about 200 nm. Transmission electron microscopy shows that the nanoparticles are relatively round in shape and have a negative potential.

[0048] The second aspect of the present invention provides a method for preparing the above-mentioned nanoparticles, the preparation method comprising:

[0049] S1. Synthesis of pHEA-b-pFcA;

[0050] S2, synthesis of pHEA-b-pIMDQ;

[0051] S3. Adding the pHEA-b-pFcA and pHEA-b-pIMDQ into a buffer solution to obtain the pHEA-b-pFcA and pHEA-b-pIMDQ by self-assembly.

[0052] There is no order of precedence between steps S1 and S2;

[0053] In step S1, the specific synthesis method of pHEA-b-pFcA includes:

[0054] Polyhydroxyethyl acrylate (pHEA), FcA-APMA and AIBN were mixed in N,N-dimethylformamide (DMF), oxygen was completely removed by freeze-thaw cycles, and polymerized overnight at 65-85°C (including 80°C) by RAFT polymerization;

[0055] Wherein, the molar ratio of pHEA, FcA-APMA and AIBN is 0.01-0.1:0.5-5:0.02-0.1, preferably 0.02:1.0:0.026;

[0056] The pHEA can be obtained commercially, but can also be prepared by RAFT polymerization. Specifically, hydroxyethyl acrylate (HEA), PABTC and AIBN are mixed in DMF, oxygen is completely removed by freeze-thaw cycles, and polymerization is carried out at 65-85° C. (including 80° C.) overnight.

[0057] Wherein, the molar ratio of HEA, PABTC and AIBN is 5-15:0.1-0.5:0.01-0.05; preferably 10:0.2:0.04.

[0058] The FcA-APMA is synthesized by an amidation reaction between the carboxyl group in FcA and the amino group in N-(3-aminopropyl)methacrylamide (APMA) using an EDC / HOBT / DIEA scheme;

[0059] Specifically, FcA, 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC), 1-hydroxybenzotriazole (HOBT) and N,N-diisopropylethylamine (DIEA) are dissolved in anhydrous dichloromethane (DCM) and stirred to obtain a mixture; then, APMA completely dissolved in N,N-dimethylformamide (DMF) is added to the above mixture and stirred overnight to obtain the product.

[0060] Among them, the molar ratio of FcA, EDC, HOBT, DIEA and APMA is 0.5-1:0.8-1.8:0.8-1.8:1.6-3.6:0.6-1.2, preferably 0.65:0.98:0.98:1.96:0.78.

[0061] In step S2, the specific method for synthesizing pHEA-b-pIMDQ includes:

[0062] First, pHEA-b-pPFP is prepared by RAFT polymerization. Specifically, pHEA, PFPA and AIBN are mixed in DMF, oxygen is completely removed by freeze-thaw cycles, and polymerization is carried out at 65-85° C. (including 80° C.) overnight to obtain the pHEA-b-pPFP, IMDQ and triethylamine. Then, 2-aminoethanol is used to further completely replace PFP. Specifically, the product is transferred to a dialysis membrane, dialyzed with water, and then freeze-dried to obtain the product.

[0063] The molar ratio of pHEA, PFPA and AIBN is 0.01-0.05:1.5-3:0.005-0.03; preferably 0.03:1.7:0.01.

[0064] The molar ratio of pHEA-b-pPFP to IMDQ is 0.05-0.5:0.2-1, preferably 0.1:0.5.

[0065] The molecular weight cut-off (MWCO) of the dialysis membrane is 1-5 kDa, preferably 3.5 kDa.

[0066] The PFPA can be purchased from the market, or prepared by the following method: dissolving pentafluorophenol and triethylamine in anhydrous DCM under an inert atmosphere; then adding completely dissolved acryloyl chloride to the mixture under an ice bath, and warming to room temperature and stirring overnight to obtain the PFPA.

[0067] Wherein, the inert atmosphere can be nitrogen, and the molar ratio of pentafluorophenol, triethylamine and acryloyl chloride is 1-2:1-2:1-2, preferably 1.08:1.19:1.19.

[0068] In step S3, the buffer may be PBS buffer, and ultrasonic dispersion (such as ultrasonic bath) is preferably used to make the mixing more uniform.

[0069] In one or more specific embodiments of the present invention, use of the above-mentioned nanoparticles in the preparation of anti-tumor drugs is provided.

[0070] Meanwhile, it should be noted that tumor is used in the present invention as known to those skilled in the art, and includes benign tumors and / or malignant tumors. Benign tumors are defined as excessive proliferation of cells that cannot form aggressive, metastatic tumors in the body. Conversely, malignant tumors are defined as cells with multiple cellular abnormalities and biochemical abnormalities that can form systemic diseases (e.g., tumor metastasis in distant organs).

[0071] In one or more specific embodiments of the present invention, the medicine of the present invention can be used to treat malignant tumors. Examples of malignant tumors that can be treated with the medicine of the present invention include solid tumors and hematological tumors. Preferably, solid tumors can be tumors of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, liver, lung, larynx and hypopharynx, mesothelioma, ovary, pancreas, prostate, rectum, kidney, small intestine, soft tissue, testicle, stomach, skin (such as melanoma), ureter, vagina and vulva.

[0072] In one or more specific embodiments of the present invention, an anti-tumor drug is provided, wherein the active ingredient of the anti-tumor drug comprises the above-mentioned nanoparticles.

[0073] According to the present invention, the medicament further comprises at least one pharmaceutically inactive ingredient.

[0074] The inactive ingredients of the drug can be carriers, excipients and diluents commonly used in pharmacy. Moreover, according to the usual methods, the drug can be made into oral preparations, external preparations, suppositories and sterile injection solutions in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, sprays, etc.

[0075] The non-drug active ingredients such as carriers, excipients and diluents that may be included are well known in the art, and a person of ordinary skill in the art can determine that they meet clinical standards, and no specific limitations are made here.

[0076] In one or more specific embodiments of the present invention, the medicine of the present invention can be administered to the subject in any known manner. For example, it can be delivered to the tissue of interest by intravenous systemic delivery or local injection. It can be optionally administered via intravenous, percutaneous, intranasal, mucosal or other delivery methods. Such administration can be carried out via single dose or multiple doses. It will be appreciated by those skilled in the art that the actual dose to be administered in the present invention can vary depending on various factors to a great extent, such as target cells, biological types or their tissues, the general condition of the subject to be treated, route of administration, mode of administration, etc.

[0077] The nanoparticle preparation of the present invention can be accumulated in tumor tissue mainly by passive targeting after intravenous injection. After being phagocytosed by cells, the ferrocene in the nanoparticles will undergo Fenton reaction when it meets excess hydrogen peroxide to produce a large number of hydroxyl free radicals. This process is accompanied by the occurrence of immunogenic cell death of tumor cells. The calreticulin gradually exposed by tumor cells and the immune adjuvant IMDQ together activate the maturation of DC cells and widely mobilize the recruitment of T lymphocytes.

[0078] In one or more specific embodiments of the present invention, the drug administration subject can be human and non-human mammals, such as rats, mice, guinea pigs, dogs, rabbits, gorillas, monkeys, etc.

[0079] In one or more specific embodiments of the present invention, a method for treating tumors is provided, comprising administering a therapeutically effective dose of the above-mentioned nanoparticles or drugs to a subject.

[0080] The subject refers to an animal, preferably a mammal, and most preferably a human, that has been the subject of treatment, observation or experiment. The "therapeutically effective amount" refers to the amount of active compounds or agents, including the compounds of the present invention, which can cause the biological or medical response of the tissue system, animal or human sought by the researcher, veterinarian, doctor or other medical personnel, including the alleviation or partial alleviation of the symptoms of the disease, syndrome, condition or disorder being treated. It must be recognized that the optimal dosage and interval of the active ingredients of the present invention are determined by their properties and external conditions such as the form, route and site of administration and the specific mammal being treated, and this optimal dosage can be determined using conventional techniques. It must also be recognized that the optimal course of treatment, that is, the daily dosage of the compound over a specified period of time, can be determined using methods known in the art.

[0081] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The test methods for the specific conditions in the following examples are usually carried out under normal conditions.

[0082] Example

[0083] 1. Test methods

[0084] 1.1 Synthesis of monomers

[0085] 1.1.1 Synthesis of APMA-FcA

[0086] APMA-FcA was synthesized by an amidation reaction between the carboxyl group in FcA and the amino group in N-(3-aminopropyl)methacrylamide (APMA) using an EDC / HOBT / DIEA scheme. In short, FcA (150.02 mg, 0.65 mmol), EDC (143.78 mg, 0.98 mmol), HOBT (101.35 mg, 0.98 mmol) and DIEA (252.85 mg, 1.96 mmol) were dissolved in anhydrous dichloromethane (DCM) and stirred for 1 h. Then, APMA (107.2 mg, 0.78 mmol) completely dissolved in N,N-dimethylformamide (DMF) was added dropwise to the mixture and stirred overnight. Afterwards, the solvent was removed by rotary evaporation and the solution was washed with a DCM / water system. The DCM layer was dried with anhydrous MgSO4 and filtered. The crude product was separated using flash chromatography with hexane: EtOAc (1:1).

[0087] 1.1.2 Synthesis of PFPA

[0088] In a round-bottom flask equipped with a stirring bar, pentafluorophenol (200.0 mg, 1.08 mmol) and triethylamine (166 μL, 1.19 mmol) were dissolved in anhydrous DCM under N2 atmosphere. The completely dissolved acryloyl chloride (101 μL, 1.19 mmol) was then added dropwise to the mixture under an ice bath for 30 minutes, and the mixture was stirred overnight after warming to room temperature. Subsequently, the mixture was washed 3 times with Milli-Q water, and the DCM layer was dried over MgSO4 and concentrated by rotary evaporation to obtain a colorless liquid PFPA.

[0089] 1.2 Synthesis of polymers

[0090] 1.2.1 Synthesis of pHEA

[0091] The typical procedure for the synthesis of pHEA via RAFT polymerization is as follows: Hydroxyethyl acrylate (HEA, 1.15 mL, 10 mmol), PABTC (47.2 mg, 0.2 mmol), AIBN (6.57 mg, 0.04 mmol) and DMF were loaded into a 25 mL Schlenk tube. Oxygen was thoroughly removed by three freeze-thaw cycles. Overnight polymerization was carried out at 80 °C, and pHEA was isolated by precipitation in cold ether and centrifugation. After redissolving in DMF, this process was repeated three times. The precipitated polymer was dried under vacuum overnight to obtain pHEA.

[0092] 1.2.2 Synthesis of pHEA-b-pFcA

[0093] To prepare the copolymer of pHEA-b-pFcA, pHEA (119.0 mg, 0.02 mmol), FcA-APMA (400 mg, 1.0 mmol), AIBN (4.2 mg, 0.026 mmol) and DMF were loaded into a 25 mL Schlenk tube, and then oxygen was thoroughly removed by three freeze-thaw cycles. Polymerization was carried out at 80 ° C overnight, and the resulting polymer was separated by precipitation in cold ether and centrifugation. After redissolving in DMF, this process was repeated three times. The precipitated polymer was dried under vacuum overnight to obtain pHEA-b-pFcA.

[0094] 1.2.3 Synthesis of pHEA-b-pIMDQ

[0095] Before obtaining pHEA-b-pIMDQ, pHEA-b-pPFP was synthesized as follows: pHEA (182.7 mg, 0.03 mmol), PFPA (404.3 mg, 1.70 mmol), AIBN (1.2 mg, 0.01 mmol) and DMF were added to a 25 mL Schlenk tube and oxygen was completely removed by three freeze-thaw cycles. The polymerization was carried out at 80 °C overnight and pHEA-b-pPFP was isolated by precipitation in cold ether three times. Subsequently, in order to replace the PFP attached to the pHEA-b-pPFP backbone with IMDQ, pHEA-b-pPFP (161.96 mg, 0.1 mmol), IMDQ (216.50 mg, 0.5 mmol) and triethylamine (40 μL) were charged into a pre-dried round-bottom flask with a stirring bar. The mixture was then stirred at 40 °C for 3 days. Finally, 2-aminoethanol was used to further completely replace PFP. They were transferred to a dialysis membrane (MWCO 3.5 kDa) and dialyzed against water for three days, and then lyophilized to obtain pHEA-b-pIMDQ.

[0096] 1.3 Preparation of nanoparticles

[0097] All different types of nanoscale drug delivery platforms (N@FcA, N@IMDQ, and N@Fc / IM) were generated by a simple self-assembly strategy. For a typical N@Fc / IM fabrication, two stock solutions of pHEA-b-pFcA and pHEA-b-pIMDQ were slowly dripped into PBS buffer in an ultrasonic bath for 30 min. For N@FcA and N@IMDQ, a single stock solution of pDMA-b-pFcA or pDMA-b-pIMDQ was slowly added into PBS buffer.

[0098] 1.4 Characterization of Nanoparticles

[0099] The particle size distribution of the nanoparticles was determined using a Zetasizer Nano ZS90 instrument. After negative staining with phosphotungstic acid (2%, wt / wt), the morphology was observed using a transmission electron microscope.

[0100] 1.5 Hydroxyl radical detection

[0101] To measure the generation of ·OH, a concentrated stock solution of 10 mg / mL APMA-FcA, a 3.2 mg / mL methylene blue solution, and a commercial hydrogen peroxide solution were prepared. 64 μL of the APMA-FcA concentrated stock solution was diluted in 1 mL of Milli-Q water. Then, hydrogen peroxide (10 mM, 1 μL) and methylene blue (3.2 mg / mL, 1 μL) were added to the mixture, and the absorbance was scanned at 660 nm by UV-vis spectroscopy.

[0102] Hydroxyl radicals can also be measured by fluorescence spectroscopy using terephthalic acid as a probe. Hydrogen peroxide (500 mM), terephthalic acid (0.5 mM) and APMA-FcA were incubated in an acetic acid buffer (pH = 4) at 40°C for 5 hours. The reaction system was then centrifuged at 10,000 rpm for 10 minutes, and the supernatant was used for fluorescence measurement.

[0103] 1.6 Cellular uptake

[0104] 4T1 in 10×10 4 Cells were seeded into 48-well plates at a density of 10 cells / well overnight, and then incubated with Nile Red and Nile Red-loaded nanoplatforms (Nile Red, equal to 2, 4, 8 μg mL-1) for 12 hours. Afterwards, cells were dissociated with cell dissociation buffer and then centrifuged at 100g for 5 minutes. Flow cytometry was performed on a BD FACS Aria III, and data were processed using the FlowJo software package.

[0105] 1.7 Cytotoxicity

[0106] 4T1 cells were cultured at 5 × 10 3 Cells were seeded at a density of 100 cells / well in a 96-well plate overnight and then incubated with a range of concentrations of N@Fc / IM (5.0 to 160 μg mL -1 ) and incubated overnight. Then, 10 μL of CCK-8 working solution was added and incubated at 37°C for 4 h. The OD value at 450 nm was measured with an enzyme-labeled instrument to evaluate the cytotoxicity.

[0107] 1.8 Maturation of BMDC

[0108] Bone marrow-derived dendritic cells (BMDCs) were obtained from the bone marrow cavity of C57BL / 6 mice and inoculated in medium containing GM-CSF (10 ng mL -1 ) and IL-4 (10 ng mL -1 ) in 6-well plates with RPMI-1640 complete growth medium. After a period of culture, BMDCs were transferred to 48-well plates overnight and then incubated with FcA, IMDQ, Fc / IM, N@FcA, N@IMDQ and N@Fc / IM for 24 hours. Then, they were labeled with anti-CD11c, anti-CD86, anti-MHC-II and anti-CD40 antibodies, and the maturation of BMDCs was observed by flow cytometry (BD FACS Celesta).

[0109] 1.9 Evaluation of tumor inhibition in mice

[0110] 4T1 breast cancer cells (1×10 6 Cell mL -1 ,0.1mL) was inoculated into the mammary fat pad of mice to establish orthotopic 4T1 female BALB / c mice. When the tumor volume reached approximately 100mm 3 At 1 pm, the mice were randomly divided into 7 groups (6 mice in each group) and injected with 100 μL of various preparations through the tail vein: I) PBS, II) FcA, III) IMDQ, IV) Fc / IM, V) N@FcA, VI) N@IMDQ and VII) N@Fc / IM (FcA, equal to 25 mg kg -1 ; IMDQ, equal to 500 μg kg -1 The length (L) and width (W) of the tumors and body weight were measured with a vernier caliper every other day.

[0111] Tumor volume was calculated by L × W × W / 2. Tumor growth curves were analyzed using GraphPad Prism 7.0.

[0112] 2. Test results

[0113] 2.1 Synthesis of monomeric APMA-FcA and monomeric PFPA

[0114] according to Figure 1 The technical route shown synthesizes monomer APMA-FcA and monomer PFPA. Figure 2 and Figure 3 Its successful synthesis was confirmed by NMR.

[0115] 2.2 Synthesis of polymers

[0116] In order to polymerize the monomer APMA-FcA and the monomer PFPA, the classic reversible addition-fragmentation chain transfer polymerization (RAFT polymerization) was used. The specific synthesis steps are as follows: Figure 4 As shown, hydrophilic pHEA was first synthesized, and then pHEA-b-pFcA and pHEA-b-pPFP were synthesized using pHEA as a chain transfer agent. IMDQ was then connected to pHEA-b-pPFP through a substitution reaction. In order to enhance the hydrophilicity of the polymer, the incompletely substituted PFP was further substituted with 2-aminoethanol to obtain the final product pHEA-b-pIMDQ. All polymers were characterized by nuclear magnetic hydrogen spectroscopy, and the molecular weight of the polymer was measured. The results are shown in Figure 5-9 shown.

[0117] 2.3 Construction and characterization of nanoparticles

[0118] The polymers were prepared into nanoparticles using self-assembly technology, such as Fig.10 As shown in the figure, the particle size is about 200nm. Transmission electron microscopy shows that the nanoparticles are relatively round in shape and have a negative potential. Fig.11 shown.

[0119] 2.4 Fenton reaction detection

[0120] In order to verify the ability of the synthesized APMA-FcA to catalyze the Fenton reaction to produce hydroxyl radicals, methylene blue and terephthalic acid were used for detection. Fig.12 As shown in the figure, after the reaction of APMA-FcA and hydrogen peroxide, the decrease of the ultraviolet absorption peak of methylene blue was obviously observed, confirming the generation of hydroxyl radicals. At the same time, the signal of hydroxyl radicals was also observed using terephthalic acid as a probe. Both experiments prove that the synthesized APMA-FcA has the ability to catalyze the Fenton reaction to produce hydroxyl radicals.

[0121] 2.5 Cellular uptake of nanoparticles

[0122] The results are as follows Fig.13 As shown, the results of the cell uptake experiment showed that the nanoparticles could be effectively taken up by tumor cells (4T1) and exhibited a concentration-dependent behavior.

[0123] 2.6 Cytotoxicity of Nanoparticles

[0124] The cytotoxicity of the nanoparticles was detected using the CCK8 kit. The results showed that the higher the concentration, the lower the cell survival rate. Fig.14 shown.

[0125] 2.7 Nanoparticles promote DC cell maturation

[0126] The drug was incubated with bone marrow-derived dendritic cells, and then the expression of mature proteins on the cell surface was detected. Fig.15 and 16 As shown, it is proved that the prepared nanoparticles have good DC activation ability.

[0127] 2.8 Nanoparticles inhibit the growth of tumor cells

[0128] A mouse breast cancer model was established and the drug was administered intravenously. The tumor growth curve of the mice was observed. Fig.17 As shown, the N@Fc / IM group had the best tumor inhibition effect, confirming the tumor inhibition potential of the prepared nanoparticles.

[0129] Matters not covered by the present invention are known technologies.

[0130] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. A nanoparticle co-linked with ferrocene and TLR7 / 8 agonist, It is characterized in that The ferrocene and TLR7 / 8 agonist are co-linked nanoparticles which are composed of a block copolymer pHEA- b -pFcA and pHEA- b -pIMDQ is obtained by self-assembly; Among them, pHEA- b The specific synthesis method of -pFcA includes: The poly(hydroxyethyl acrylate) pHEA, FcA-APMA and AIBN were mixed in N,N-dimethylformamide DMF, and the oxygen was completely removed by freeze-thaw cycles, and the polymerization was carried out at 65-85°C overnight by RAFT polymerization. Wherein, the molar ratio of pHEA, FcA-APMA and AIBN is 0.01-0.1:0.5-5:0.02-0.1; The pHEA is prepared by RAFT polymerization, specifically, hydroxyethyl acrylate HEA, PABTC and AIBN are mixed in DMF, oxygen is completely removed by freeze-thaw cycles, and polymerization is carried out at 65-85° C. overnight; Wherein, the molar ratio of HEA, PABTC and AIBN is 5-15:0.1-0.5:0.01-0.05; The FcA-APMA is synthesized by an EDC / HOBT / DIEA scheme through an amidation reaction between a carboxyl group in FcA and an amino group in N-(3-aminopropyl)methacrylamide APMA, specifically, FcA, 1-ethyl-(3-dimethylaminopropyl)carbodiimide EDC, 1-hydroxybenzotriazole HOBT and N,N-diisopropylethylamine DIEA are dissolved in anhydrous dichloromethane DCM and stirred to obtain a mixture; then, APMA completely dissolved in N,N-dimethylformamide DMF is added to the above mixture and stirred overnight to obtain the obtained product; Wherein, the molar ratio of FcA, EDC, HOBT, DIEA and APMA is 0.5-1:0.8-1.8:0.8-1.8:1.6-3.6:0.6-1.2; pHEA- b The specific synthesis method of -pIMDQ includes: Firstly, RAFT polymerization method was used to polymerize pHEA- b -pPFP, specifically, pHEA, PFPA and AIBN are mixed in DMF, oxygen is completely removed by freeze-thaw cycles, and polymerized at 65-85°C overnight to obtain the pHEA- b -pPFP, IMDQ and triethylamine are mixed and stirred, and then 2-aminoethanol is used to further completely replace PFP. Specifically, the product is transferred to a dialysis membrane, dialyzed with water, and then freeze-dried to obtain; The molar ratio of pHEA, PFPA and AIBN is 0.01-0.05:1.5-3:0.005-0.03; The pHEA- b -The molar ratio of pPFP to IMDQ is 0.05-0.5:0.2-1.

2. The ferrocene and TLR7 / 8 agonist co-linked nanoparticles as claimed in claim 1, It is characterized in that The nanoparticles have uniform particle sizes, round shapes, and negative potential.

3. The ferrocene and TLR7 / 8 agonist co-linked nanoparticles as claimed in claim 1, It is characterized in that The average particle size of the nanoparticles is 200 nm.

4. A method for preparing the nanoparticles according to any one of claims 1 to 3, It is characterized in that The preparation method comprises: S1, pHEA- b - Synthesis of pFcA; S2, pHEA- b -Synthesis of pIMDQ; S3, the pHEA- b -pFcA and pHEA- b -pIMDQ was added to the buffer and obtained by self-assembly; There is no particular order in which steps S1 and S2 are performed.

5. Use of the nanoparticles according to any one of claims 1 to 3 in the preparation of anti-tumor drugs.

6. An anti-tumor drug, It is characterized in that The active ingredient of the anti-tumor drug comprises the nanoparticles according to any one of claims 1 to 3.